Effects ofUGT1A1genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer

Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients

(2013) Ling-Zhi Wang et al.   PLoS One

Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era

(2012) Mladen Tzvetkov et al.   PATHOLOGY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab

(2011) Janet S. Lee et al.   Pharmacogenetics and Genomics

Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk

(2010) Z.-Y. Hu et al.   CLINICAL CANCER RESEARCH

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

(2009) Erika Cecchin et al.   JOURNAL OF CLINICAL ONCOLOGY

Etoposide pathway

(2009) Jun Yang et al.   Pharmacogenetics and Genomics

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH